Summary: In a phase 1 first-in-human programme, the oral small-molecule GLP-1 receptor agonist ECC5004/AZD5004 was administered as single doses of 1 to 300 mg in healthy volunteers and as multiple daily doses of 5, 10, 30 and 50 mg over 28 days in patients with type 2 diabetes mellitus. The compound bound the human GLP-1 receptor (IC = 2.4 nM), was well tolerated with no serious adverse events, and produced dose-dependent reductions in glucose and body weight, with dose-proportional exposure at doses of 25 mg or higher. These are early safety and pharmacodynamic signals, not proven clinical efficacy.
PICO Summary
| Element | Detail |
|---|---|
| Population | Healthy adult volunteers (single-ascending-dose phase) and patients with type 2 diabetes mellitus (multiple-ascending-dose phase); supported by non-clinical work in human GLP-1R cell lines and non-human primates. Phase 1 first-in-human study (NCT05654831), multicentre. |
| Intervention | ECC5004/AZD5004, an oral once-daily small-molecule GLP-1 receptor agonist. Single doses 1 to 300 mg (healthy volunteers); multiple daily doses 5, 10, 30 and 50 mg for 28 days (T2DM). Exact per-arm sample sizes are not reported in the abstract. |
| Comparison | Placebo (double-blind, placebo-controlled). No active GLP-1 receptor agonist comparator arm was included; head-to-head claims against marketed agents are not supported. |
| Outcome | Human GLP-1R binding IC = 2.4 nM; cAMP signalling augmented without beta-arrestin-2 recruitment or receptor internalisation. Well tolerated with no serious adverse events; mild gastrointestinal effects. Dose-dependent reductions in glucose and body weight; dose-proportional exposure at doses of 25 mg or higher. The abstract reports no formal effect sizes, 95% confidence intervals, p values, or ARR/NNT, as expected for a phase 1 study. |
Expert Commentary
This work establishes that ECC5004/AZD5004 is an orally bioavailable, once-daily small-molecule GLP-1 receptor agonist with a binding and signalling profile consistent with the class, and that early human exposure was safe over 28 days. The verdict is that the molecule has cleared its first-in-human hurdle and shown plausible pharmacodynamic signals, but nothing here demonstrates clinical efficacy. The headline of dose-dependent glucose and weight reduction should be read as an early signal in a small, dose-finding population, not as a treatment effect that has been quantified or powered. The single most important limitation is design altitude itself: a phase 1 study is built to characterise safety, tolerability and pharmacokinetics, so it carries no effect sizes, confidence intervals or controlled efficacy comparison, and the favourable framing must be tempered by the absence of any active comparator. It should also be noted that the work was sponsored by the manufacturers, AstraZeneca and Eccogene, with several authors employed by the sponsors, which warrants the usual caution around early-stage industry data. Can I use this with my patients? Not yet, because no patient should be offered an unapproved investigational agent outside a trial on the strength of phase 1 data. The reasonable course is to watch the phase 2 readouts, where controlled efficacy against glucose and weight will determine whether this oral candidate earns a place alongside established therapies.
References
Haggag AZ, Xu J, Butcher L, et al. Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist. Diabetes Obes Metab. 2025;27(2):551-562. doi:10.1111/dom.16047
